Highlights from ASCO GU 2018
ASCO GU 2018 Prostate Cancer
- ASCO GU 2018: Phase II Trial of 6 Months ADT/Abiraterone Acetate Plus Prednisone and Definitive Radiotherapy - Intermediate to High Risk Localized Prostate Cancer - AbiRT Trial
- ASCO GU 2018: Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate Cancer
- ASCO GU 2018: Clinical Utility of Foundation One Tissue Molecular Profiling in Men with Metastatic Prostate Cancer
- ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic Castrate Resistant Prostate Cancer
- ASCO GU 2018: Retrospective Analysis of Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide
ASCO GU 2018 Bladder Cancer
- ASCO GU 2018: Erdafitinib, (FGFR) a Pan-fibroblast Growth Factor Receptor Inhibitor, in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations
- ASCO GU 2018: Docetaxel with or without Ramucirumab After Immune Checkpoint Inhibition in Platinum-refractory Metastatic Urothelial Carcinoma (Muc): Prespecified Subgroup Analysis from the Phase 3 Range Trial
- ASCO GU 2018: Size-focality-invasion in Upper Tract Urothelial Carcinoma - A Novel Imaging-Based Score To Predict Survival Outcomes
- ASCO GU 2018: Effectiveness of Transurethral Resection Plus Systemic Chemotherapy as Definitive Treatment for Muscle-Invasive Bladder Cancer
- ASCO GU 2018: Impact of Number of Cycles of Platinum-based First-line Chemotherapy for Advanced Urothelial Carcinoma
ASCO GU 2018 Renal Cancer
- ASCO GU 2018: The CLEAR study: A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma
- ASCO GU 2018: Self-reported Quality of Life as a Predictor of Survival in Renal Cell Carcinoma
- ASCO GU 2018: Treatment Facility Volume and Survival in Patients with metastatic Renal Cell Carcinoma
- ASCO GU 2018: Carcinomas of the Renal Medulla: A Comprehensive Genomic Profiling Study
- ASCO GU 2018: Association of Dividing Pathologically Upstaged T3a Renal Cell Carcinoma with Improved Alignment of Outcomes: A Call for TMN Revision
ASCO GU 2018 Penile, Urethral, Testicular and Adrenal Cancers
- ASCO GU 2018: Adrenal Cortical Carcinoma: Finding the Wolf in Sheep’s Clothing
- ASCO GU 2018: Thromboembolic Complications in Germ Cell Tumor Patients: Should Use of Peripherally Inserted Central Catheters be Pursued?
- ASCO GU 2018: Effect of Number of CT Scans During Follow-Up of Patients with Clinical Stage I Seminoma: A Trial-Level Meta-Analysis
- ASCO GU 2018: Is Surveillance without Immediate Treatment an Option for Newly Diagnosed Testicular Germ-cell Cancer Patients with Borderline Size Retroperitoneal Lymph Nodes on CT Scan?
- ASCO GU 2018: High-Dose Chemotherapy and Stem-Cell Rescue - Salvage Treatment for Germ Cell Testicular Tumors in Second- and Third-Line, and Outside Clinical Trials
ASCO GU 2018 Press
- Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer Announced at 2018 ASCO Genitourinary Cancers Symposium
- Bayer to Feature Prostate Cancer Research at ASCO GU 2018 Symposium
- Apalutamide Delays Prostate Cancer Metastases by More Than Two Years
- New Model Predicts Survival for People with Bladder Cancer Receiving Immunotherapy
- Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, with Fewer Side Effects